The target for LDL cholesterol (LDL-C) in CKD The guidelines for

The target for LDL cholesterol (LDL-C) in CKD The guidelines for dyslipidemia therapy in CKD from K/DOQ1: below LDL-C 130 mg/dL, the first step is lifestyle modification; above LDL-C 130 mg/dL, drug therapy should be contemplated in addition to lifestyle modification, including diet therapy, weight control, and exercise. Evidence-Based Practice Stem Cells antagonist Guideline for the Treatment of Diabetes in Japan 2007 recommends that the target for lipid control is less than 120 mg/dL of

LDL-C among diabetic CKD patients. The Guidelines for Prevention of Atherosclerotic Disease in Japan also set the same target for lipid control in a high-risk group (three or more risk factors) or in cases with diabetes, cerebral infarction, or peripheral artery disease. CKD is a critical risk factor for CVD, and thus LDL-C is lowered down to less than 120 mg/dL. If possible, the target for LDL-C should be stricter:

less than 100 mg/dL. There is not enough evidence relating to the target of dyslipidemia treatment for Japanese patients with CKD. Resolution of this issue must await future studies.”
“The number of dialysis patients Selleckchem AT9283 due to end-stage kidney disease is increasing worldwide, which is becoming a burden on health economics. End-stage kidney disease due to diabetic nephropathy is increasing

worldwide. The development of chronic kidney disease (CKD) is associated with atherosclerosis caused by lifestyle-related diseases such as diabetes and hypertension. CKD is most likely to cause cardiovascular disease, hospitalization Protein kinase N1 or death, thus threatening nations’ health. The number of end-stage kidney disease patients is ever-increasing in Japan as well as the rest of the world The number of end-stage kidney disease (ESKD) patients requiring dialysis or renal transplantation is increasing markedly in every part of the world. It is predicted that the number of such patients will increase as much as fivefold from 430,000 to 2,100,000 over a 20-year period from 1990 to 2010. This rapid increase can be appreciated when compared to the prediction that diabetes patients will increase by about 1.

This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>